Linpei Jia1, Qiang Jia2, Jingyan Yang3, Rufu Jia3, Hongliang Zhang4. 1. Department of Nephrology, Xuanwu Hospital of Capital Medical University, Beijing, Chinaanny_069@163.com. 2. Department of Nephrology, Xuanwu Hospital of Capital Medical University, Beijing, China. 3. Central Hospital of Cangzhou, Cangzhou, China. 4. Department of Life Sciences, the National Natural Science Foundation of China, Beijing, China.
Abstract
BACKGROUND/AIMS: Dysbiosis of the intestinal microbiota may accelerate the progression of chronic kidney disease (CKD) by increasing the levels of urea toxins. In recent years, probiotics have been recognized to maintain the physiological balance of the intestinal microbiota. In this study, we aim to assess the therapeutic effects of probiotics on CKD patients with and without dialysis via meta-analysis. METHODS: We conducted a meta-analysis of randomized controlled trials (RCTs) by searching the databases of Pubmed, EMBASE and Cochrane Library (No. CRD42018093080). Studies on probiotics for treatment of CKD adults lasting for at least 4 weeks were selected. The primary outcomes were the levels of urea toxins, and the second outcomes were the levels of interleukin (IL)-6, C-reactive protein (CRP) and hemoglobin (Hb). The risk of bias was assessed by Cochrane Collaboration' tool, and the quality of evidence was appraised with the Grading of Recommendation Assessment. Means and standard deviations were analyzed by random effects analysis. Stratified analysis was done and sensitivity analysis was performed when appropriate. RESULTS: Totally, eight studies with 261 patients at CKD stage 3 to 5 with and without dialysis were included. We found a decrease of p-cresyl sulfate (PCS) of 3 studies with 125 subjects (P = 0.01, SMD -0.57, 95% CI, -0.99 to -0.14, I2 = 25%) and an increase of IL-6 in 3 studies with 134 subjects (P = 0.03, 95% CI, SMD 0.37, 0.03 to 0.72, I2 = 0%) in the probiotics groups. Analysis of serum creatinine (P = 0.47), blood urine nitrogen (P = 0.73), CRP (P = 0.55) and Hb (P = 0.49) yielded insignificant difference. CONCLUSION: Limited number of studies and small sample size are limitations of our study. Probiotics supplementation may reduce the levels of PCS and elevate the levels of IL-6 whereby protecting the intestinal epithelial barrier of patients with CKD.
BACKGROUND/AIMS: Dysbiosis of the intestinal microbiota may accelerate the progression of chronic kidney disease (CKD) by increasing the levels of urea toxins. In recent years, probiotics have been recognized to maintain the physiological balance of the intestinal microbiota. In this study, we aim to assess the therapeutic effects of probiotics on CKD patients with and without dialysis via meta-analysis. METHODS: We conducted a meta-analysis of randomized controlled trials (RCTs) by searching the databases of Pubmed, EMBASE and Cochrane Library (No. CRD42018093080). Studies on probiotics for treatment of CKD adults lasting for at least 4 weeks were selected. The primary outcomes were the levels of urea toxins, and the second outcomes were the levels of interleukin (IL)-6, C-reactive protein (CRP) and hemoglobin (Hb). The risk of bias was assessed by Cochrane Collaboration' tool, and the quality of evidence was appraised with the Grading of Recommendation Assessment. Means and standard deviations were analyzed by random effects analysis. Stratified analysis was done and sensitivity analysis was performed when appropriate. RESULTS: Totally, eight studies with 261 patients at CKD stage 3 to 5 with and without dialysis were included. We found a decrease of p-cresyl sulfate (PCS) of 3 studies with 125 subjects (P = 0.01, SMD -0.57, 95% CI, -0.99 to -0.14, I2 = 25%) and an increase of IL-6 in 3 studies with 134 subjects (P = 0.03, 95% CI, SMD 0.37, 0.03 to 0.72, I2 = 0%) in the probiotics groups. Analysis of serum creatinine (P = 0.47), blood urine nitrogen (P = 0.73), CRP (P = 0.55) and Hb (P = 0.49) yielded insignificant difference. CONCLUSION: Limited number of studies and small sample size are limitations of our study. Probiotics supplementation may reduce the levels of PCS and elevate the levels of IL-6 whereby protecting the intestinal epithelial barrier of patients with CKD.
Authors: Jalal Bohlouli; Iman Namjoo; Mohammad Borzoo-Isfahani; Mohammad Ali Hojjati Kermani; Zakiyeh Balouch Zehi; Amir Reza Moravejolahkami Journal: Heliyon Date: 2021-01-10
Authors: Tan Rui-Zhi; Diao Hui; Li Jian-Chun; Zhong Xia; Wang Xiao-Jia; Wen Dan; Fan Jun-Ming; Wang Li Journal: Front Physiol Date: 2020-11-27 Impact factor: 4.566
Authors: Amir Reza Moravejolahkami; Mohammad Ali Hojjati Kermani; Zakiyeh Balouch Zehi; Seyed Mohammad Sadegh Mirenayat; Marjan Mansourian Journal: J Diabetes Metab Disord Date: 2021-02-23
Authors: Alonso Jerez-Morales; José S Merino; Sindy T Díaz-Castillo; Carlos T Smith; Jorge Fuentealba; Humberto Bernasconi; Gerson Echeverría; Apolinaria García-Cancino Journal: Toxins (Basel) Date: 2021-03-07 Impact factor: 4.546